MK-2206 2HCl

Catalog No.S1078

MK-2206 2HCl Chemical Structure

Molecular Weight(MW): 480.39

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 180 Publications

19 Customer Reviews

  • Inhibition of AKT signaling abolishes MKK4 phosphorylation on Ser78 in injured axons. Cultures of sensory neurons were treated with 5 µM MK-2206 or 5 µM GDC-0068 for 1 hr prior to axotomy. Axonal proteins harvested at indicated time points after axotomy were subjected to immunoblot analysis.

    Cell, 2015, 160(1-2): 161-76 . MK-2206 2HCl purchased from Selleck.

    Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck.

  • The PI3K or AKT inhibition does not restore sensitivity to WZ4002 in PC9 WZR. PC9GR4 or WZR10 cells were treated with WZ4002 alone at the indicated concentrations or in combination with the AKT inhibitor MK-2206 (1 uM). MK-2206 effectively inhibited AKT in both cells.

    Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck.

    Rap1b negatively regulates neutrophil transcellular migration by limiting PI3K-Akt signaling. (A-D) Effect of Akt inhibitor MK2206 (2 uM), Src inhibitor PP2 (10 uM), or vehicle control (DMSO) on WT or Rap1b-/- neutrophil functions. (A) Percentage of neutrophil transendothelial migration in 3D migration model. (B) ECM degradation assessed on Oregon green-labeled gelatin matrix; (left) representative images on (bar, 10 um) and (right) bar graph is percentage of matrix degradation. (C) Percentage of cells forming multiple protrusions. (D) Percentage of neutrophils present at junction of activated bEND.3 in 3D migration assay. Mean ?SD; n = 3 independent experiments. **, P < 0.01; ***, P < 0.001; NS, not significant using unpaired Student's t test).

    J Exp Med 2014 211(9), 1741-58. MK-2206 2HCl purchased from Selleck.

  • VE-cadherin-induced Akt activation mediates YAP phosphorylation and translocation in ECs. HUVECs were starved for 1h and treated with thrombin (1U) for 1h. Total cell lysates were probed with anti-pAkt, Akt or b-actin antibody. The representative blots of three independent experiments are depicted, and the normalized values for p-Akt are shown. HUVECs were cultured and starved as described as in d and incubated for 8h in complete medium with the Akt inhibitor, MK-2206 (1 uM). pAkt, Akt, pYAP and YAP were detected by western blotting using specific antibodies.

    Nat Commun 2015 6:6943. MK-2206 2HCl purchased from Selleck.

    Inhibitors of AKT or ERK overcome SDF-1a-mediated resistance to ibrutinib-triggered PARP and caspase 3 cleavage in CXCR4S338X-expressing BCWM.1 cells. CXCR4S338X-expressing WM cells were treated with ibrutinib (0.5 uM) alone or in the presence of SDF-1a (20 nM) and/or the AKT inhibitors MK-2206 (0.5 uM) and AZD-5363 (0.5 uM); or the MEK inhibitors AS-703026 (0.25 uM), AZD-6244 (0.5 uM) and UO126 (5.0 uM). (a) Immunoblotting results for phosphoAKT (S473) and phospho-ERK (T202/Y204) in CXCR4S338X-expressing BCWM.1 cells pretreated with ibrutinib with and without AKT or ERK inhibitors, then subjected to SDF-1a stimulation for 2 min. The inhibitory effect of AZD-5363 on AKT, which is known to paradoxically hyper-phosphorylate pAKT(S473) was confirmed by inhibition of the phospho-activity for the downstream AKT targets glycogen synthase kinase 3b and pS6. (b) Immunoblotting results for cleaved PARP and cleaved caspase 3 in CXCR4S338X-expressing BCWM.1 cells treated with ibrutinib and/or AKT or ERK inhibitors for 6 h at IC50 doses. GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

    Leukemia 2015 29(1), 169-76. MK-2206 2HCl purchased from Selleck.

  • Induction of apoptosis positively correlates with FOXO3a protein levels and phosphorylation. (a) Treatment of 11 cell lines seeded in 6-well plates with 8 μM MK-2206 or DMSO for 48 hours. Nuclei were harvested for PI staining and FACS analysis and the differences between drug and no drug are displayed as in Figure b. Both conditions were performed in triplo for each cell line. Below the FACS data is a we stern blot of cell lysates from this panel treated with 8 μM MK-2206 or DMSO and harvested at 24 hours. Each cell line name corresponds to the two western lanes below it and the four cell cycle bars above it.

    Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck.

    IC50 values for an Akt inhibitor (MK-2206) and a MEK inhibitor (U0126) in a panel of mouse and human anaplastic (ATC) and follicular (FTC) carcinoma cell lines. On the bottom, a Western blotting showing the effect on the activation of Akt and ERK1/2 of one hour exposure to these inhibitors (MK-2206: 500 nM, U0126: 10 μM).

    Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck.

  • Mean IL-8 concentrations determined by ELISA of the supernatants of HeLa cells infected with wild-type Salmonella. Kinase inhibitors are indicated on the x axis, and the target families of the inhibitors are indicated above each column. CEC, chelerythrine; Pim Inh, Pim-1 inhibitor 2. Inhibitors that significantly affected IL-8 production relative to the control (P < 0.05, Bonferroni post hoc test from one-way ANOVA) are indicated with an asterisk. Relative cell viability is also shown, as determined by reduction of XTT by viable cells. A450, absorbance at 450 nm.

    Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck.

    Reducing cellular levels of PtdIns5P by overexpression of PIP4Kα inhibits clonogenic growth of U2OS but enhances cell survival in response to H2O2 stimulation. A) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), PI-103 (0.5 μM), U0126 (5 μM), or SB203580 (5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown. B) U2OS cells (1000) were plated, allowed to attach overnight, and then treated with DMSO (control), MK-2206 (1 μM), triciribine (1 μM), KU0063794 (1 μM), or PI-103 (0.5 μM) for 9 d. Cell colonies were stained using crystal violet. Dried plates were scanned. Representative results are shown.

    FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck.

  • A. Western blot analysis of pAKT activation in ovarian cancer cell lines treated with exogenous IGF-1. B. Activation of pAKT by IGF-1 in low-grade ovarian cancer cell lines was blocked by the AKT inhibitor MK-2206 in a dose-dependent manner.

    Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck.

    Confocal microscopy images of NO formation. DAF 2 DA-loaded washed platelets (1.0109 platelets/mL) were preincubated at 378C with saline (A), and then stimulated for 1min with 0.1 (B), 1.0 (C) or 10 (D) μM AEA. In Panel (E-F-G) washed platelets were preincubated with 1 μM SR1 (E), 1 Mm MK2206 (F) or 20 μM LY294002 (G), and then stimulated for 1min with 1.0 μM AEA. In panel (H) is reported the effect of 5 mg/mL collagen, used as a positive control. All the experiments were carried out in the presence of 100 μM L-arginine. NO formation was visualized by confocal microscropy as detailed in Methods.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • The AEA effect on eNOS phosphorylation. Washed platelets (1.0109 platelets/mL), preincubated at 378C with saline, 1 μM SR1, 1 μM SR2, 20 μM LY294002, 1 μM MK2206, 1.0 μM EGTA, or 30 μM BAPTA/AM, were stimulated for 1 min with 1.0 μM AEA. At the end of incubation suitable aliquots were immunoblotted with anti-p-eNOSser1177 as detailed in Methods.Blots are representative of five independent experiments.

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

    Effect of selected agents on NOx and cGMP formation induced by AEA. Washed platelets (1.0109 platelets/mL), prewarmed at 378C with saline or 1mM SR1, 1 μM SR2, 20 μM URB597 (URB), 1 μM MK2206 (MK) or 20 μM LY294002 (LY), were incubated for 1min with 100 μM L-arginine in the presence of 1.0 μM AEA. NOx (panel A) and cGMP (panel B) content were determined as detailed in Methods. Each bar represents the meanSD of five independent experiments carried out in triplicate. Student,s t-test: P <0.0001 versus none;P <0.0005; P <0.005 versus AEA

     

     

    J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck.

  • C.U87MG cells were treated with vehicle or 1 μM MK-2206 for 1 hr, and then irradiated with 6 Gy. Total cell lysate was harvested 1 hr after IR and subjected to Western blot analysis with the indicated antibody. Cells without IR treatment were used as a control.

    D. Cells were treated with vehicle (control) or 1 μM MK-2206 for 1 hr, then irradiated with indicated dosage. 4 hr after IR, cells were fed with drug-free medium, and incubated for another 20 hr at 37°C, after which they were trypsinized and seeded for clonogenic survival assay. Colony-forming efficiency was determined 14 d later.
     

     

    Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck.

    MK-2206 2HCL inhibited the sorafenib-induced PI3K/mTOR pathway activation and enhanced the cytotoxic effects of sorafenib in resistant cell lines. (A) HUH-7 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved PARP were revealed by Western blotting. (B) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) for 24 h with or without pretreatment with specific kinase inhibitors (MK-2206 2HCL, 15 μM). The expressions of p-AKT and cleaved RARP were revealed by Western blotting. (C) HUH-7 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (D) SK-HEP-1 hepatoma cells treated with sorafenib (5 μM) with or without the kinase inhibitors for 24 h. The proportions of apoptotic cells were evaluated by annexin V labeling. (*P < 0.05, HUH-7, SK-HEP-1 are control groups, R-HUH-7, R-SK-HEP-1 are resistant groups).

    J Surg Res, 2016, 206(2):371-379. MK-2206 2HCl purchased from Selleck.

  • Comparative effects of inhibitors by immunofluorescence microscopy study. Confluent HC11 cells were grown on poly-L-lysine-coated glass coverslips (immunofluorescence) and on plastic plates (biochemical control) and then treated with inhibitors according to the standard procedure. Upper part: the biochemical action of the inhibitors was tested to validate the immunofluorescence results. Cellular proteins were analyzed by SDS-PAGE and the immunoblots were successively probed with anti-ADRP, anti-β-casein, and anti- β-actin antibodies and their respective HRP-conjugated secondary antibodies. Each experimental condition was performed in duplicate. Lower part: cells were fixed, permeabilized and subjected to immunofluorescence microscopy using antiserum against ADRP and TRITC-conjugated secondary antibody (red).

    Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of MK-2206 for 3h,followed by 15-minute stimolation of 100ng/ml EGF.

     
     

     

    Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck.

  •  

    PI3K pathway signaling in GDC-0941 and MK-2206 treated MCF-7 derivatives with PIK3CA or  AKT1 mutations. Cells were grown in medium containing 5% FBS and treated with vehicle or increasing concentrations of GDC-0941 (0 nM, 50 nM, 100 nM, and 400 nM) or MK-2206 (0 nM, 100 nM, 250 nM, 1000 nM). After 24 hours of drug treatment, lysates were prepared and equal amounts of protein were load ed onto SDS-PAGE gels and blotted with the indicated antibodies.

    MK-2206 2HCl purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.
Targets
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
8 nM 12 nM 65 nM
In vitro

MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
NCI-H292 NXfGbZdPS3m2b4TvfIlkKEG|c3H5 MYGzJO69VQ>? NHniR|Q4OiCq NEXXeIRFVVOR Ml3iTY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25? MX:yNFU4OTB4OR?=
A431 MXnLbY5ie2ViQYPzZZk> NWD5fWpRPSEQvF2= M372VVUhcA>? NF72[YRFVVOR NXPkXGtpW3WycILld5NmeyC2aHWgd4lodmGuaX7nJI9nKEGtdDDhcoQhTXKt NUPOSFF7OjB3N{GwOlk>
HepG2 NVPyd3lMS3m2b4TvfIlkKEG|c3H5 NGrOeoIyOCEQvF2= M2K5UFI1KGh? NX\xdm5qTE2VTx?= NWjMUZhCW2Wwc3n0bZpmeyC{ZYPpd5RidnRiY3XscJMhfG9idHjlJIN6fG:2b4jpZ{Bm\m[nY4Sgc4Yhe2:{YX\lcolj NF;WdFgzOTJyNUmyOS=>
Sk-Hep1 NXvqdGtmS3m2b4TvfIlkKEG|c3H5 M3j2UlExKM7:TR?= NVLwPWx{OjRiaB?= NGrKRWtFVVOR M2fVd3NmdnOrdHn6[ZMhemW|aYP0ZY51KGOnbHzzJJRwKHSqZTDjfZRwfG:6aXOg[YZn\WO2IH;mJJNwemGoZX7pZi=> MXyyNVIxPTl{NR?=
OCUT1 cells harbored PIK3CA (H1047R+/+) MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIr2eoE{KM7:TR?= MYi1JIQ> MmLISG1UVw>? M1PpWGlEPTB;MD6xOEDPxE1? MYiyNVI5QTJ4Nx?=
K1 cells harbored PIK3CA (E542K+/+) NYDaT4JtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXrOZM{KM7:TR?= NWm1VXR1PSCm NVzxOms3TE2VTx?= MYrJR|UxRTBwNUKg{txO MkfFNlEzQDl{Nke=
FTC133 cells harbored PTEN (allele deletion and R130+) MkLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXezJO69VQ>? MnHBOUBl NYTFfWJCTE2VTx?= NF7VOodKSzVyPUCuNVgh|ryP M1fmTlIyOjh7Mk[3
C643 cells harbored HRAS (G13R+/−) NXzMSI51T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLTS|BROyEQvF2= Ml\5OUBl NEfwVYRFVVOR NUfwfFBOUUN3ME2wMlI4KM7:TR?= MoP1NlEzQDl{Nke=
Hth7 cells harbored NRAS (Q61R+/−) MlXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXYcnlSOyEQvF2= M3PMW|Uh\A>? MmrxSG1UVw>? M4\VfmlEPTB;ND61JO69VQ>? NXLGVlZrOjF{OEmyOlc>
TPC1 cells harbored RET/PTC1 rearrangement NFzqb|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:zJO69VQ>? MnHXOUBl M1fGNmROW09? MX\JR|UxRTBwNUmg{txO NV:5W3FqOjF{OEmyOlc>
Hth74 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnyXIg{KM7:TR?= NWPRR3dKPSCm NYThVnlVTE2VTx?= Mn25TWM2OD1{LkG5JO69VQ>? NIjiRpAzOTJ6OUK2Oy=>
KAT18 M{nOeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPPeFU6OyEQvF2= M{XHWFUh\A>? NYSxeFkxTE2VTx?= NXXNPIlOUUN3ME20MlYzKM7:TR?= NYnFZot{OjF{OEmyOlc>
SW1736 NGHSNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2THc|ExOCEQvF2= M4T0fVUh\A>? MlfJSG1UVw>? MWHJR|UxRTR5LkW2JO69VQ>? M4Pi[VIyOjh7Mk[3
WRO MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HK[|ExODBizszN Mkf4OUBl M1LacmROW09? MkOyTWM2OD5zMECwJO69VQ>? NUi3fZdvOjF{OEmyOlc>
TAD2 M{\yTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL6NVAxOCEQvF2= M1m4Z|Uh\A>? M3nLdGROW09? M1XWUGlEPTB-MUCwNEDPxE1? MkLyNlEzQDl{Nke=
LN229 NUf4e41mSXCxcITvd4l{KEG|c3H5 M2XFVlAvPSEQvF2= NH7rN203OCCq Mn7JSG1UVw>? MoW0RZVodWWwdIOgZZBweHSxZ3XubYMh\W[oZXP0d{Bw\iCpZX\peIlvcWJ? MXKyNlA2PzlzNB?=
T98G M1TwUGFxd3C2b4Ppd{BCe3OjeR?= NXL0cJZuOC53IN88US=> NI\lcFM3OCCq NIf0UFdFVVOR NXrrWG1WSXWpbXXueJMh[XCxcITv[4VvcWNiZX\m[YN1eyCxZjDn[YZqfGmwaXK= Mn6zNlIxPTd7MUS=
HC11 NI\LS21HfW6ldHnvckBCe3OjeR?= MkPzNVAh|ryP NHrhbIszPCCq NXO0[mQ2TE2VTx?= NXXmXYwyUW6qaXLpeJMh|rJvY3Hz[YlvKGGwZDDBSHJRKHO7boTo[ZNqew>? NYfGcHhNOjJ2Mk[2NlE>
MOLT-4 NV\oTWtiS3m2b4TvfIlkKEG|c3H5 M4TpeVExKM7:TR?= MX20PEBp MVHEUXNQ NVjEeWtDUUN3ME2xMlfjiIoQvF2= Mnz5NlI3OTR{NEO=
CEM-R Mnu3R5l1d3SxeHnjJGF{e2G7 M1jOe|ExKM7:TR?= MlXDOFghcA>? NH:3UZFFVVOR NETmO5FKSzVyPUOuN-KBkc7:TR?= NWC0ZWdEOjJ4MUSyOFM>
CEM-S MVjDfZRwfG:6aXOgRZN{[Xl? M3LjW|ExKM7:TR?= MX60PEBp NWj1eolwTE2VTx?= M2faWGlEPTB;NT6x5qCK|ryP MnzNNlI3OTR{NEO=
MOLT-4 NHzqZWZHfW6ldHnvckBCe3OjeR?= M17QNVExKM7:TR?= M4Pwd|I1KGh? MVjEUXNQ M{S1[2Jtd2OtczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2Vib3[geIhmKGOnbHygZ5lkdGV? MnS1NlI3OTR{NEO=
MOLT-4 MmjhSpVv[3Srb36gRZN{[Xl? NGriOWg16oDLzszN M1XCdlQhcA>? M{jaNGROW09? M4\rdmlv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFOzRU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>? M4DnTFIzPjF2MkSz
CEM-R NXLK[FZTTnWwY4Tpc44hSXO|YYm= NEflOmc16oDLzszN NHf4WY41KGh? Mo\ESG1UVw>? Mo\RTY5kemWjc3XzJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CCOQ{TBM2ItKGFid3XscE1me3SjYnzpd4hm\CCjdYTvdIhi\3libXHyb4Vz M1z2VlIzPjF2MkSz
CEM-S NUXMeYhtTnWwY4Tpc44hSXO|YYm= MkfsOQKBkc7:TR?= NHftT2c1KGh? NEHV[HRFVVOR M4f6c2lv[3KnYYPld{B1cGViYX3veY51KG:oIHPs[YF3\WRiTFO1RU9DNCCjIIflcIwu\XO2YXLsbZNp\WRiYYX0c5Bp[We7IH3hdotmeg>? M{Pa[|IzPjF2MkSz
HepG2 cell NEW2NVNMcW6jc3WgRZN{[Xl? NXT2Tmh{OjBizszN MmnONlQhcA>? NXXUUnJ1TE2VTx?= NI\t[|lFd3ewcnXneYxifGW|IITo[UBxcG:|cHjvdplt[XSrb36gc4YhSUuW NYjqc2xrOjN5OUezNVk>
HepG2 cell MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4f6NVMxKM7:TR?= NFHa[XAzPCCq MnfPSG1UVw>? M1XEVGlvcGmkaYTzJINmdGxiZ4Lve5Rp MnPKNlM4QTd|MUm=
HepG2 cell NHntNmhCeG:ydH;zbZMhSXO|YYm= M4n1XlIxKM7:TR?= MljONlQhcA>? NV\0WVViTE2VTx?= MVPJcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3r0XFI{Pzl5M{G5
GEO NV\vd4VYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnB[pNqPTByIH7N M4HMcFczKGh? MonKSG1UVw>? M4HVdGlvcGmkaYTzJINmdGxiZ4Lve5Rp MVeyOFU5OTJ|MR?=
CNE-1 NXz0RoVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqxNEDPxE1? MYK5OkBp NWfONpNxTE2VTx?= MYLJR|UxRTJwOU[g{txO M1\rXVI2OzN4OUK1
CNE-2 NYjlUYd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW3NVAh|ryP NELBUGU6PiCq MkXFSG1UVw>? MnfXTWM2OD12LkWzJO69VQ>? NX3jZ|JZOjV|M{[5NlU>
HONE-1 M1HOT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1ziRVExKM7:TR?= NUDiUHVHQTZiaB?= MYjEUXNQ NEexVoRKSzVyPUOuN|ch|ryP MoDmNlU{OzZ7MkW=
SUNE-1 NIrUPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3zNIg3OTBizszN M{PxbFk3KGh? M{KxWmROW09? NWPPTHplUUN3ME2wMlUzKM7:TR?= NFL5OowzPTN|NkmyOS=>
CNE-2 MnzoSpVv[3Srb36gRZN{[Xl? MmOyNVAh|ryP M4H5UFQ5KGh? Ml3SSG1UVw>? MkDkTY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDheEBIOQ>? M3npelI2OzN4OUK1
HONE-1 MUTGeY5kfGmxbjDBd5NigQ>? MYmxNEDPxE1? Mn;qOFghcA>? MU\EUXNQ NIXlO|hKdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KEdz MYSyOVM{Pjl{NR?=
NEC8 M1m4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3sZ2NKSzVyPUCuNFk3PTFizszN NVjtTnZuW0GQR1XS
P12-ICHIKAWA NFPp[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rRUWlEPTB;MD6xNVYzKM7:TR?= NVmwWZZ5W0GQR1XS
MDA-MB-175-VII M1HVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIL6TlRKSzVyPUCuNVM4OzhizszN MmnwV2FPT0WU
AsPC-1 MkfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLycnZiUUN3ME2wMlIzOTJ{IN88US=> MmLiV2FPT0WU
T47D M3zaTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTBwMkiyOUDPxE1? NEnhTINUSU6JRWK=
HH NUK1elI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrJR|hKSzVyPUCuN|AzQDNizszN M4rwTHNCVkeHUh?=
MOLT-16 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnrSZFKSzVyPUCuN|A{OiEQvF2= NEH1emJUSU6JRWK=
ES5 MofSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrSfIhKSzVyPUCuN|Q1PTVizszN MnzqV2FPT0WU
RS4-11 Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwM{S2NUDPxE1? NIqwPIRUSU6JRWK=
KARPAS-45 NFz2WJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTQO3ZKSzVyPUCuN|c{OjFizszN NY\YT4lzW0GQR1XS
NCI-H720 M1vSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUK2ZWRXUUN3ME2wMlM4Pjd7IN88US=> M{fjVXNCVkeHUh?=
H9 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTBwM{i4PFMh|ryP NYjUUpN3W0GQR1XS
EFM-19 MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXf0WVlSUUN3ME2wMlQ1ODFizszN NVH0ZoVnW0GQR1XS
SBC-1 NGrlV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTBwNESwN|Uh|ryP MXnTRW5ITVJ?
A4-Fuk MmO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUWyOFd5UUN3ME2wMlQ3QDZ6IN88US=> NFiwOWhUSU6JRWK=
NCI-H1563 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XXU2lEPTB;MD60PFE5QSEQvF2= NXnkV2JyW0GQR1XS
HCC1419 M1;yUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwNEi4PVIh|ryP MknpV2FPT0WU
H-EMC-SS NFr4WW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwNEm5N|kh|ryP NGrteG9USU6JRWK=
BHT-101 NIj6NGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPp[o9KSzVyPUCuOVI6PjFizszN NV;4OGlWW0GQR1XS
IGROV-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LudWlEPTB;MD61OVI1QSEQvF2= MV3TRW5ITVJ?
HGC-27 MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTR[nJNUUN3ME2wMlU3Pzh|IN88US=> NGnvb4hUSU6JRWK=
MDA-MB-361 NInIOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M175V2lEPTB;MD61O|c3OSEQvF2= M4i2V3NCVkeHUh?=
KE-37 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDNc4dHUUN3ME2wMlU5OjZizszN NYnhWFVxW0GQR1XS
HCC70 NUTpS5RiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrJfGJKSzVyPUCuOVk5OjdizszN MlPRV2FPT0WU
LNCaP-Clone-FGC M4\acWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\0NWlEPTB;MD62NVA1QCEQvF2= MnvUV2FPT0WU
HAL-01 M3KzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwNkKxN{DPxE1? MoroV2FPT0WU
HT NUXQcItRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwNkOyN|kh|ryP NIjmU3VUSU6JRWK=
MDA-MB-415 M{[zR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;TR493UUN3ME2wMlY{PjJ4IN88US=> M2XwN3NCVkeHUh?=
NOS-1 NXf4[5F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwNkO3NlMh|ryP MU\TRW5ITVJ?
DU-145 Mk\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLCTWM2OD1yLk[0O|Q2KM7:TR?= NFjCUVJUSU6JRWK=
OCUB-M MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXVT2hkUUN3ME2wMlcxQTZ4IN88US=> NH;Pc45USU6JRWK=
VA-ES-BJ NYj1SlVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnz5TWM2OD1yLkezNFI2KM7:TR?= M3nSTnNCVkeHUh?=
J-RT3-T3-5 Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTBwN{S0NFMh|ryP M{HkRnNCVkeHUh?=
MOLT-4 NWTGVWtwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXPZppKSzVyPUCuPFA2QDJizszN NY[3TmYzW0GQR1XS
NB7 M{jvSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTBwOEK0NVEh|ryP MnLDV2FPT0WU
L-363 NYO0NVlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXUU4NMUUN3ME2wMlg{PDR{IN88US=> NGSxPG9USU6JRWK=
NKM-1 MlHiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\6cWlEPTB;MD64OlI2OyEQvF2= MlzaV2FPT0WU
HOP-92 MmXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1P3cmlEPTB;MD64O|IzOyEQvF2= M{LRUHNCVkeHUh?=
OAW-42 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M176TWlEPTB;MD64PFczKM7:TR?= MYTTRW5ITVJ?
HuO9 NX7q[m9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDETWM2OD1yLkmyO|UyKM7:TR?= M2TlNnNCVkeHUh?=
MFE-280 NXrUOpZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jYdWlEPTB;MD65OlQ3PSEQvF2= NUnpU5hwW0GQR1XS
EM-2 MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTBwOUe5N|kh|ryP NYjhWXZ5W0GQR1XS
NCI-H520 NGeybm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVrrV40zUUN3ME2wMlk5PTl{IN88US=> MnfuV2FPT0WU
LB2241-RCC NEixbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjpOIZjUUN3ME2wMlk6PzN2IN88US=> MXnTRW5ITVJ?
SK-NEP-1 NVrxNpJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwMUS0PFUh|ryP MWnTRW5ITVJ?
LXF-289 NEWyUY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknTTWM2OD1zLkG3NVU3KM7:TR?= M1zKSXNCVkeHUh?=
EPLC-272H NFrrUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz3TWM2OD1zLkG3NlU3KM7:TR?= MnnkV2FPT0WU
COLO-684 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fWdWlEPTB;MT6yN|czPSEQvF2= NHvUTmJUSU6JRWK=
ES1 NGfxcohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlziTWM2OD1zLkK0NFY2KM7:TR?= NXTGe|VSW0GQR1XS
DOHH-2 M{fGRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTFwMkiyNFMh|ryP NWPGdndLW0GQR1XS
CTB-1 M3;Ob2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFewSmpKSzVyPUGuNlg6QSEQvF2= MV7TRW5ITVJ?
G-401 MoPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELNO|VKSzVyPUGuNlk4QTVizszN Mn:0V2FPT0WU
LoVo NVfQTot[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwM{K1N|Qh|ryP NYLpUVV4W0GQR1XS
Ramos-2G6-4C10 M2HCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf5TWM2OD1zLkOzO|AyKM7:TR?= M1zHWnNCVkeHUh?=
MFM-223 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vEVmlEPTB;MT6zOFQ3OSEQvF2= M3zoOHNCVkeHUh?=
PA-1 MlHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\BbG5XUUN3ME2xMlM2OjZ3IN88US=> Mn\hV2FPT0WU
697 M{DmVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPCR4RKSzVyPUGuN|c3OTZizszN NYjSOmJYW0GQR1XS
QIMR-WIL MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvVenNqUUN3ME2xMlQ6OTF4IN88US=> M3;WV3NCVkeHUh?=
HOS M3zuSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHnFSphKSzVyPUGuOFk2PThizszN M3zQVnNCVkeHUh?=
DMS-273 NG\1O|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmK3TWM2OD1zLkWxPVU6KM7:TR?= MnTCV2FPT0WU
ME-180 NYfIcWFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXwZY04UUN3ME2xMlU3QDlzIN88US=> Ml:zV2FPT0WU
HCC2218 Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrTOGZKSzVyPUGuOlgzOjVizszN MWDTRW5ITVJ?
CAL-54 NFPMWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1v5eWlEPTB;MT63NVI1OiEQvF2= MVLTRW5ITVJ?
OMC-1 M1P3VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TRdGlEPTB;MT63OFY4PyEQvF2= MVXTRW5ITVJ?
COR-L105 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X2[GlEPTB;MT63PVc{PyEQvF2= NVHEem5NW0GQR1XS
BV-173 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVK2UlJXUUN3ME2xMlgyODd2IN88US=> MnzEV2FPT0WU
RKO M{PYdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTFwOEexNFEh|ryP MlnnV2FPT0WU
SNU-387 NV;YPW9DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW0TWM2OD1zLki4OFA3KM7:TR?= NYfXZ|FrW0GQR1XS
SW1088 M2r3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXvJR|UxRTFwOUS2NFYh|ryP MYXTRW5ITVJ?
Hs-578-T MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml33TWM2OD1{LkGxOFM{KM7:TR?= NED6[YlUSU6JRWK=
OC-314 Mm\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2i1S2lEPTB;Mj6xOVA5PiEQvF2= MoCwV2FPT0WU
RMG-I Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3L3emlEPTB;Mj6xOlM6QCEQvF2= MnuyV2FPT0WU
NCI-H1395 MoXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ixc2lEPTB;Mj6xPFA6OSEQvF2= NVXtUGRHW0GQR1XS
GAMG M4P6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfaTWM2OD1{LkKzPFQ2KM7:TR?= MXXTRW5ITVJ?
LB1047-RCC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf5VoZSUUN3ME2yMlI1OzF5IN88US=> M2r0SXNCVkeHUh?=
MN-60 M{\FTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;ye2I4UUN3ME2yMlI6QTJ|IN88US=> MWDTRW5ITVJ?
OAW-28 NXLlWlQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXraRVNtUUN3ME2yMlI6QTVzIN88US=> NV:2OJJpW0GQR1XS
NCI-H2228 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPJV2NXUUN3ME2yMlMyPTV{IN88US=> MXfTRW5ITVJ?
ABC-1 MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTZTWM2OD1{LkOzNlU{KM7:TR?= MX7TRW5ITVJ?
LS-513 MlG2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj1eZZ7UUN3ME2yMlM{PDh2IN88US=> M33YenNCVkeHUh?=
KS-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\vN2lEPTB;Mj6zPFE6OSEQvF2= MV\TRW5ITVJ?
NB69 NH7xcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXTTWM2OD1{LkO4PVg{KM7:TR?= NVHZcYFOW0GQR1XS
VM-CUB-1 NXH5flRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTJwM{mwPFMh|ryP MoDBV2FPT0WU
D-423MG MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;OTWM2OD1{LkSxNFQ1KM7:TR?= MmDTV2FPT0WU
EW-18 M1nhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D3NWlEPTB;Mj60NVk{QSEQvF2= M3rZdHNCVkeHUh?=
YH-13 M13wOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHkPJBKSzVyPUKuOFYyPTNizszN NV3rSFR3W0GQR1XS
T-24 NIPlbWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zlPGlEPTB;Mj60O|g5OSEQvF2= NFLOc5VUSU6JRWK=
ES8 NUe1TFU2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTJwNEmyPFch|ryP NWTBc3V3W0GQR1XS
ES3 NHvTd4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfhfGlyUUN3ME2yMlQ6PzV7IN88US=> MnjZV2FPT0WU
RXF393 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJwNkC0PFch|ryP M1fjbnNCVkeHUh?=
RPMI-8226 NEfKNIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJwNkK5OVMh|ryP MnPXV2FPT0WU
AGS M1[5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEj4flNKSzVyPUKuO|IyOzdizszN NUPGcJByW0GQR1XS
HCC1395 NI\RWnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4W3NGlEPTB;Mj63OVE5PyEQvF2= NWXBTVM2W0GQR1XS
MV-4-11 M3Sxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJwN{WyOlYh|ryP NVXvZm5XW0GQR1XS
A204 NEPTWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTJwOEO4O|Ih|ryP MYHTRW5ITVJ?
MCF7 NF6wOXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID0bYhKSzVyPUKuPFYyOTdizszN NEf1WGtUSU6JRWK=
SNU-423 NHr6U2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTJwOEmyOFIh|ryP NI\EOYpUSU6JRWK=
NCI-H1048 NYnDWYdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTJwOU[4OlUh|ryP NGLEWlJUSU6JRWK=
GR-ST M3nDeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjPN2RKSzVyPUOuNFQ3OTFizszN NIXw[YNUSU6JRWK=
EoL-1- NVLjVHpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTNwMEewOVgh|ryP NIi3d2JUSU6JRWK=
HuH-7 NXXMSGRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTNwMEm0OlQh|ryP MYPTRW5ITVJ?
OS-RC-2 MneyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILueI9KSzVyPUOuNVEyQSEQvF2= NVXmPG5oW0GQR1XS
EW-3 NWKw[YFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;KRo5KSzVyPUOuNVk2OjlizszN MYHTRW5ITVJ?
NCI-H747 NVjCfng{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjBeoZKSzVyPUOuNlA3QTRizszN MUfTRW5ITVJ?
EW-16 NUXnS2JHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTNwMkG4O|kh|ryP M{fHW3NCVkeHUh?=
DOK NITpRXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXTXlZKSzVyPUOuNlI5PTlizszN NHvteYlUSU6JRWK=
HCC2157 NYrEZ5d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXnTWM2OD1|LkO4NVc6KM7:TR?= M3vzfnNCVkeHUh?=
OVCAR-3 M2jrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfYVYlKSzVyPUOuOFA4QDZizszN NXPnXnUxW0GQR1XS
NCI-H1623 MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVewN5NnUUN3ME2zMlQyOjJ2IN88US=> M{fRXnNCVkeHUh?=
H4 M1HPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknkTWM2OD1|LkS1OlI3KM7:TR?= MX7TRW5ITVJ?
SW1710 M1PZOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LmSmlEPTB;Mz60OlY4QCEQvF2= MnjZV2FPT0WU
RT-112 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTNwNUKzPFgh|ryP MXLTRW5ITVJ?
DMS-114 NUXnN5F3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTNwNkKyO|gh|ryP NHrXfZlUSU6JRWK=
AN3-CA NF7MPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLhTWM2OD1|Lk[yOFU3KM7:TR?= MYPTRW5ITVJ?
KNS-62 Ml:1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH3WVNKSzVyPUOuOlM{OzhizszN M3r2VnNCVkeHUh?=
SJRH30 NHn5dI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjFV4JKSzVyPUOuOlkyOjJizszN MnH6V2FPT0WU
G-402 NGHoTHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTNwN{C3NVEh|ryP NEXnWIRUSU6JRWK=
MHH-PREB-1 M3vn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2X4R2lEPTB;Mz63NlA{QCEQvF2= NV24TYdDW0GQR1XS
P30-OHK M{C3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTNwOEC5O|Yh|ryP NUi4NGRWW0GQR1XS
RVH-421 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MorqTWM2OD1|LkixO|g5KM7:TR?= NXHvUYxiW0GQR1XS
LU-134-A M3jLbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTZWVJFUUN3ME2zMlg5PDJ6IN88US=> MV7TRW5ITVJ?
ECC10 M2P6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13QOmlEPTB;Mz65N|YzOiEQvF2= M4G5TXNCVkeHUh?=
TGW M4LFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfRflhKSzVyPUSuNFI{ODVizszN NIK0bllUSU6JRWK=
MLMA M3LTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLZXXpKSzVyPUSuNFI6PjZizszN MmTjV2FPT0WU
SCC-25 NHXScFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTRwME[1OlYh|ryP NX7hdlVPW0GQR1XS
TYK-nu MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTRwMEm1N|Qh|ryP NFjBZ4dUSU6JRWK=
LAMA-84 M4i4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XUcWlEPTB;ND6xOFE6OSEQvF2= NIXWUYNUSU6JRWK=
Calu-3 NUfPW|d{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fzbmlEPTB;ND6yOFQyPiEQvF2= NIDvVoNUSU6JRWK=
NCI-H460 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTRwMk[0OFMh|ryP M4fNfHNCVkeHUh?=
EGI-1 NWn0e|huT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTRwM{e3O|gh|ryP MXHTRW5ITVJ?
NCI-H292 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjjTWM2OD12LkO4NVQ3KM7:TR?= M4izNHNCVkeHUh?=
HCE-T M3m1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojhTWM2OD12LkSxOVc6KM7:TR?= MYPTRW5ITVJ?
EW-11 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTRwNEG4N|gh|ryP NVvXeG14W0GQR1XS
ATN-1 NHOxVppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTRwNESzNFQh|ryP M1[xNXNCVkeHUh?=
NB5 NHLTVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H6VWlEPTB;ND61N|Y6PyEQvF2= NWXVXmhEW0GQR1XS
KLE MofLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrKTWM2OD12LkewNVk5KM7:TR?= M3PMZ3NCVkeHUh?=
CAL-39 NFLwUXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PlNmlEPTB;ND63NlE1PiEQvF2= MYfTRW5ITVJ?
TI-73 M4S2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPxS2V6UUN3ME20MlgxPjB7IN88US=> NFnrTYVUSU6JRWK=
HO-1-N-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6yPG5KSzVyPUSuPVQzKM7:TR?= NYDKNXZRW0GQR1XS
786-0 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1X3b2lEPTB;ND65OFY4OyEQvF2= NY\tO3BsW0GQR1XS
SK-N-DZ MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTzTWM2OD12Lkm2NVQzKM7:TR?= NHfWN|JUSU6JRWK=
NCI-H446 NXe2NotNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXJTWVHUUN3ME21MlIxODB7IN88US=> NFjubWdUSU6JRWK=
ETK-1 NF;LXFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nwbGlEPTB;NT6yNVE3PSEQvF2= MnPkV2FPT0WU
BT-20 MonJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7sW4k{UUN3ME21MlIyOzV|IN88US=> NX;CVmsxW0GQR1XS
MEL-HO NEPOc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTVwM{ezN|Yh|ryP NIrMR45USU6JRWK=
CAL-27 MkHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzldWVtUUN3ME21MlQ3OzN7IN88US=> Ml\OV2FPT0WU
SW872 Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTVwNUm0Nlgh|ryP NFTQeGJUSU6JRWK=
RPMI-2650 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfITJpKSzVyPUWuOlYyQTlizszN NUXpbXZrW0GQR1XS
PFSK-1 NFjVXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTCTWM2OD13LkeyO|MzKM7:TR?= MknmV2FPT0WU
SF295 M4rOO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPMPHlKSzVyPUWuPFA3OzNizszN MmLNV2FPT0WU
Becker Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nKNmlEPTB;NT64OlQ4OiEQvF2= NWDNblUzW0GQR1XS
Saos-2 Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;1TWM2OD13Lki2OVMh|ryP MnHqV2FPT0WU
SK-OV-3 M3fO[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\ZcGlEPTB;NT65PVgyPiEQvF2= MmDnV2FPT0WU
VMRC-RCZ M1SwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DLXGlEPTB;Nj6wPFc4OyEQvF2= NEDNO3VUSU6JRWK=
EW-22 NXPhbpRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHlTWM2OD14LkG5OlQ6KM7:TR?= NUfqeIc5W0GQR1XS
BT-474 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPDTWM2OD14LkKzN{DPxE1? M4nvRXNCVkeHUh?=
BFTC-909 M2TafWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGmweppKSzVyPU[uN|A{PDVizszN MUjTRW5ITVJ?
NB12 NVvxOJRoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLKTWM2OD14LkO5NFcyKM7:TR?= NGDlepBUSU6JRWK=
D-263MG NG\vS2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTZwNEWxOlkh|ryP NFHjNnFUSU6JRWK=
SNB75 NF3WbndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHQTWM2OD14Lk[wNVQ{KM7:TR?= M{DM[HNCVkeHUh?=
A704 M{[5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;qZ5JKSzVyPU[uOlMxPiEQvF2= Mmn0V2FPT0WU
NCI-H1693 M4L4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nSOGlEPTB;Nj62N|YxPCEQvF2= NXrvSGtRW0GQR1XS
LN-405 M4PseWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{ixcGlEPTB;Nj63PVY4OiEQvF2= M1TIOnNCVkeHUh?=
CHL-1 M2W4Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\BN2lEPTB;Nj64NFA4QSEQvF2= M32yO3NCVkeHUh?=
A498 MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3PTWM2OD14LkixPVYyKM7:TR?= NFH6O3VUSU6JRWK=
TE-12 NXr6ZVVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\FeIRKSzVyPU[uPFM5OTdizszN MXPTRW5ITVJ?
TE-6 MlvVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT5TWM2OD14LkmzNFM5KM7:TR?= MljMV2FPT0WU
AU565 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MleyTWM2OD14Lkm2PVU4KM7:TR?= M{X5TXNCVkeHUh?=
RD NITOfplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHhTWM2OD14Lkm4Nlg1KM7:TR?= M3nodHNCVkeHUh?=
SW1463 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnhTWM2OD15LkGxNVY5KM7:TR?= MkfEV2FPT0WU
LU-99A NVnJRnZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzXOVBuUUN3ME23MlE1OzJ{IN88US=> MV7TRW5ITVJ?
NCI-H28 M3[4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HRTWlEPTB;Nz6yPVI1KM7:TR?= Mnm1V2FPT0WU
MC-IXC MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfjeFg3UUN3ME23MlQ5PTd4IN88US=> MVTTRW5ITVJ?
GP5d M{LSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTdwNEi3OlQh|ryP M4T5d3NCVkeHUh?=
GB-1 NH75cHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fu[mlEPTB;Nz61OFgxPCEQvF2= NGTEdZlUSU6JRWK=
CAL-33 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XwWmlEPTB;Nz62OlI{OyEQvF2= MX;TRW5ITVJ?
MSTO-211H NHvkZ4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\VUos2UUN3ME23MlY4OzN4IN88US=> M3q3bHNCVkeHUh?=
TE-5 NETlSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofwTWM2OD15Lke5N|M1KM7:TR?= MlHBV2FPT0WU
D-566MG MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\TV|hwUUN3ME24MlA1PDJ7IN88US=> NIHXRWdUSU6JRWK=
JVM-3 MmfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4frbWlEPTB;OD6xOVI3QCEQvF2= NXHOXnk5W0GQR1XS
T98G MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjtUGNKSzVyPUiuNVgxPjdizszN M3HKNXNCVkeHUh?=
HCC1954 M37PS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;VOZNKSzVyPUiuOFUyODRizszN M1X0e3NCVkeHUh?=
SF126 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXRXGJWUUN3ME24MlQ2QTN4IN88US=> NH;4fmtUSU6JRWK=
LB996-RCC Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe5dIlKSzVyPUiuOVMzPTdizszN MYrTRW5ITVJ?
SKG-IIIa M2rrW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkH0TWM2OD16Lk[zNFY6KM7:TR?= MVPTRW5ITVJ?
NCI-SNU-1 MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLyTWM2OD16Lk[0OlQ{KM7:TR?= MlfrV2FPT0WU
LB771-HNC NX\YOJp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n0WmlEPTB;OD62OFY6PiEQvF2= NXyyUmk2W0GQR1XS
SCC-4 M37wW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRThwNkiyNVkh|ryP NYHnN2tKW0GQR1XS
CAMA-1 NE[3eFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TGUGlEPTB;OD63O|E1PiEQvF2= M4jIZXNCVkeHUh?=
D-502MG MofGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrBc2pKSzVyPUiuO|g3OjlizszN NIKybnNUSU6JRWK=
ESS-1 NFnkNpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTSTWM2OD16Lki4O|A1KM7:TR?= M32yeHNCVkeHUh?=
HEC-1 NUP3bG9kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRThwOEm4OlYh|ryP MkDnV2FPT0WU
NB10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NICwUpNKSzVyPUmuNFIzOjRizszN M3;jdHNCVkeHUh?=
8505C NVTyNXQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILtcFZKSzVyPUmuNFQzOzJizszN NGfKe4NUSU6JRWK=
EFO-27 NWrDb|V2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIi2V|BKSzVyPUmuNVY1OTJizszN M1\1[HNCVkeHUh?=
HN MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mof0TWM2OD17LkG2OlI5KM7:TR?= MonJV2FPT0WU
DSH1 Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTlwMkC4O{DPxE1? MoLKV2FPT0WU
NBsusSR MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\vcndxUUN3ME25MlI4PDB{IN88US=> MojNV2FPT0WU
LS-123 M2i5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTlwM{G3OlEh|ryP NV:5U21OW0GQR1XS
SHP-77 NYH0OHB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K0ZWlEPTB;OT6zPVk{PSEQvF2= NEXudWxUSU6JRWK=
ACN M1vVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTlwNUOyO|ch|ryP NGHEZ2tUSU6JRWK=
U251 MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXkWYM1UUN3ME25MlY2PTR2IN88US=> MnHnV2FPT0WU
A431 Mk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrrNYFpUUN3ME25MlgxOjN6IN88US=> NV\5OWFDW0GQR1XS
5637 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG2OItKSzVyPUmuPFQ6QDRizszN NULVNmRIW0GQR1XS
MDA-MB-157 MlzYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDNTWM2OD17LkmyPFc5KM7:TR?= MXfTRW5ITVJ?
A101D NH;OOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLGUWlKSzVyPUmuPVk6PzRizszN M{HuPHNCVkeHUh?=
YKG-1 MmL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrJ[VdPUUN3ME2xNE4zODB4IN88US=> MWXTRW5ITVJ?
LAN-6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrubXZQUUN3ME2xNE4zOTZ2IN88US=> MXHTRW5ITVJ?
OVCAR-5 NXLudHI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnielliUUN3ME2xNE4zPDN|IN88US=> Mn\sV2FPT0WU
A549 M3Pmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\0OWVKSzVyPUGwMlM6PzNizszN MUTTRW5ITVJ?
no-11 M2LUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIq5O5dKSzVyPUGwMlQ{PTNizszN MWHTRW5ITVJ?
SF539 MmTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPqZ3U4UUN3ME2xNE46ODRzIN88US=> MXrTRW5ITVJ?
A388 M1LnVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\rTWM2OD1zMT6zPFk4KM7:TR?= MUTTRW5ITVJ?
DEL M2nBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFzLkSyOEDPxE1? MYDTRW5ITVJ?
SW954 NUPJPIFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFzLkS2Olgh|ryP M3H0R3NCVkeHUh?=
TK10 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrXU2hKSzVyPUGxMlUzPzFizszN MkPCV2FPT0WU
SW756 NH\mT2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLkXYlZUUN3ME2xNU42Ojl2IN88US=> M2n0UnNCVkeHUh?=
PC-3 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFzLkW3OlQh|ryP Mne0V2FPT0WU
ONS-76 M4TRSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2H1ZWlEPTB;MUGuOlM3KM7:TR?= NGj1N3VUSU6JRWK=
A427 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDTTWM2OD1zMT63NFk{KM7:TR?= NV;FdGlCW0GQR1XS
MEG-01 M{Cz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFzLke1NFkh|ryP M4\1VHNCVkeHUh?=
BB30-HNC NGDkO|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\F[WlEPTB;MUGuO|k5OiEQvF2= M4PyR3NCVkeHUh?=
NCI-H1299 M1XiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P3RWlEPTB;MUGuPFA6OyEQvF2= MkjyV2FPT0WU
GCT MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTFzLkiyNlgh|ryP NY\R[nNmW0GQR1XS
D-247MG M3zmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXTTWM2OD1zMT65OlY{KM7:TR?= MXLTRW5ITVJ?
CFPAC-1 NULrTJNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYD6RnRsUUN3ME2xNU46Pzh{IN88US=> NFrwOYZUSU6JRWK=
EKVX MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPXTWM2OD1zMj6wN|E{KM7:TR?= NYTqbJN2W0GQR1XS
CAL-51 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXnTWM2OD1zMj6wO|E3KM7:TR?= NVmwfph7W0GQR1XS
BB49-HNC NF7xenBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPiSXZZUUN3ME2xNk4yOTd5IN88US=> MVvTRW5ITVJ?
RPMI-7951 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYGzTZBpUUN3ME2xNk4yQDV2IN88US=> MUfTRW5ITVJ?
RH-1 NVm2[mdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXaTWM2OD1zMj6yNVg1KM7:TR?= MXrTRW5ITVJ?
BCPAP NU\HO4h7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPjTWM2OD1zMj60O|Q6KM7:TR?= MWrTRW5ITVJ?
GCIY MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTF{LkWyNFkh|ryP NV\iOHFjW0GQR1XS
KNS-81-FD M3LPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjqVW5KSzVyPUGyMlU5PjlizszN MXzTRW5ITVJ?
KYSE-140 MmLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYHNS4M1UUN3ME2xNk45PTl3IN88US=> M1X1cHNCVkeHUh?=
Ca-Ski MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrzXmJXUUN3ME2xNk46ODRzIN88US=> MV;TRW5ITVJ?
TGBC1TKB M1LUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrIcHE5UUN3ME2xNk46OTF3IN88US=> M{D1fXNCVkeHUh?=
HCC1187 M1HLOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTF|LkG5NVIh|ryP M2L4ZXNCVkeHUh?=
SJSA-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrGOHl6UUN3ME2xN{4zOzJ5IN88US=> MoD5V2FPT0WU
CTV-1 NVnIVo1IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkn5TWM2OD1zMz6zOFUh|ryP NYPBWXo{W0GQR1XS
WM-115 M{XkT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF|Lk[0PFMh|ryP M3LiUnNCVkeHUh?=
CHP-212 M1PRVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PzOGlEPTB;MUOuPVc{QSEQvF2= NWTXPVJsW0GQR1XS
SCC-15 MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWq5[2s2UUN3ME2xN{46Pzd3IN88US=> M{DienNCVkeHUh?=
BPH-1 NUXjbHY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m2fWlEPTB;MUSuNVY3PCEQvF2= NELwVYZUSU6JRWK=
SW780 M3rQdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3hTHJKSzVyPUG0MlUxOjVizszN M2DBPXNCVkeHUh?=
NCI-H2291 M13CRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfsVHBKSzVyPUG0MlU5PzhizszN NGTzbnVUSU6JRWK=
JEG-3 MmLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzrSndDUUN3ME2xOE43OzJ4IN88US=> NYrVPJByW0GQR1XS
CAL-120 NXrGNXlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTF2LkewNlch|ryP NULaeVQzW0GQR1XS
NCI-H23 NYO0dGZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTF2Lke5PVch|ryP NVvKcG92W0GQR1XS
MS-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1OyS2lEPTB;MUSuPVYyOSEQvF2= M1n4T3NCVkeHUh?=
PC-14 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIWwUHlKSzVyPUG0Mlk3PTRizszN Mmj0V2FPT0WU
D-283MED NHXmU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfsU2tKSzVyPUG1MlAyOTFizszN MnfLV2FPT0WU
OE19 NXz4eZczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTF3LkG1OFEh|ryP MkjEV2FPT0WU
CAS-1 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH4ZWloUUN3ME2xOU41OTh2IN88US=> MnyzV2FPT0WU
NCI-H727 NIT6Z2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\0TWM2OD1zNT60NlIyKM7:TR?= NV3hWFJEW0GQR1XS
SiHa NVvEemsxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXr[VE1UUN3ME2xOU44PTl2IN88US=> MoTaV2FPT0WU
BFTC-905 MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7tVpFJUUN3ME2xOU44Pjl2IN88US=> M{XZXXNCVkeHUh?=
MDA-MB-453 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3THWmlEPTB;MU[uNVY1OiEQvF2= MkG2V2FPT0WU
HuP-T3 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\LelFKSzVyPUG2MlY{PzNizszN MmfWV2FPT0WU
SK-LU-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnWOYNKSzVyPUG2MlY6PTZizszN MkXPV2FPT0WU
Detroit562 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTF4LkezNVgh|ryP MkfwV2FPT0WU
HCC1569 NVjrPZRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF4LkizN|ch|ryP NVLoVHduW0GQR1XS
SK-MES-1 NIr4VoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni4TWM2OD1zNj64OFE6KM7:TR?= MoLwV2FPT0WU
BB65-RCC NILTdXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjCVYFKSzVyPUG3MlA1PzlizszN M{nnWHNCVkeHUh?=
LOXIMVI MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3jOGlnUUN3ME2xO{4xPzB5IN88US=> NGjlbm5USU6JRWK=
SW1783 NV75e|Y3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF5LkGyPEDPxE1? MUjTRW5ITVJ?
NH-12 M3jv[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX3JR|UxRTF5LkOzNFMh|ryP M13kS3NCVkeHUh?=
UACC-257 MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrQNoMzUUN3ME2xO{42PTF{IN88US=> M2DsVXNCVkeHUh?=
KOSC-2 NIOzfVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFK2OFlKSzVyPUG3MlY4PTdizszN NImzVHZUSU6JRWK=
KG-1 NWDXfnNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P2VmlEPTB;MUeuOlk{PyEQvF2= NEO2WWJUSU6JRWK=
M059J M33wOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17GNGlEPTB;MUeuO|A{KM7:TR?= MYDTRW5ITVJ?
MHH-NB-11 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPHfpBKSzVyPUG3Mlk3PzNizszN Mnj0V2FPT0WU
EW-1 NFHW[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXRTWM2OD1zOD6xN|gzKM7:TR?= MmK3V2FPT0WU
CAL-85-1 M{TsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTF6LkKzOVch|ryP NGPHb4NUSU6JRWK=
639-V MnnPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XHd2lEPTB;MUiuN|M2PCEQvF2= NIThV2JUSU6JRWK=
C32 NHP2bZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DQSmlEPTB;MUiuOFczPyEQvF2= NFPrWYhUSU6JRWK=
KM-H2 M1\I[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELMVY9KSzVyPUG4MlUzOzJizszN M1[1eXNCVkeHUh?=
A253 NUfoSmcyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTF6LkeyPFYh|ryP M{jlbXNCVkeHUh?=
NCI-N87 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXv2NoFtUUN3ME2xPE46ODB6IN88US=> NXXDVFN2W0GQR1XS
8-MG-BA NFroWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2i4UGlEPTB;MUmuNFY1PiEQvF2= MmHaV2FPT0WU
GI-ME-N Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvjU2FKSzVyPUG5MlE2PDZizszN NHHkW29USU6JRWK=
8305C MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTF7LkKyPFYh|ryP MnS3V2FPT0WU
TE-8 NI\KfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13QRWlEPTB;MUmuN|AzPCEQvF2= MmfGV2FPT0WU
KYSE-270 NUH6Onl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzUdnVKSzVyPUKwMlAzOTdizszN NFmzUo5USU6JRWK=
HL-60 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TWUmlEPTB;MkCuNFk1OSEQvF2= NX7uVoxwW0GQR1XS
Mo-T MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHYbnBKSzVyPUKwMlE3PjVizszN NFHn[4NUSU6JRWK=
NCI-H1355 M1fQNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2q2NmlEPTB;MkCuN|M4PCEQvF2= MYnTRW5ITVJ?
HT-1080 NEPXfHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnLTG9KSzVyPUKwMlU1QTdizszN MWHTRW5ITVJ?
MIA-PaCa-2 NV22UZdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI[2XHBKSzVyPUKwMlY5QDNizszN NXvWTJZZW0GQR1XS
NCI-H441 M3rSV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfXTWM2OD1{MD63N|c6KM7:TR?= M2m2XHNCVkeHUh?=
LCLC-97TM1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvreWJCUUN3ME2yNE45OTN2IN88US=> NXTQSm1TW0GQR1XS
HT-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK5RWNKSzVyPUKxMlU3OzFizszN NHjNT2RUSU6JRWK=
22RV1 NVXSXGI6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17QRmlEPTB;MkGuOVY5PSEQvF2= NF[0NGxUSU6JRWK=
LK-2 M2nQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrNVmFKSzVyPUKxMlU6PTNizszN MoGwV2FPT0WU
CW-2 M{P6[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHy1NpFKSzVyPUKxMlYxPjlizszN MmP1V2FPT0WU
KYSE-510 NX\nZ251T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPZXpA6UUN3ME2yNU43ODl3IN88US=> M3fiVXNCVkeHUh?=
CGTH-W-1 M2XQWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGr5S3hKSzVyPUKxMlcyPjZizszN MmDhV2FPT0WU
NCI-H661 NFvI[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlr5TWM2OD1{Mj6wN|Qh|ryP MXrTRW5ITVJ?
KU-19-19 Mnq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDmTWM2OD1{Mj6xOlk4KM7:TR?= MoWxV2FPT0WU
NCI-H2122 M2HOSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXhTWM2OD1{Mj6yOFMzKM7:TR?= Mn;vV2FPT0WU
NCI-H526 M1[zeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTJ{LkO4PVUh|ryP NX7lNXhkW0GQR1XS
NCI-H1650 NYTFZmZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVqx[JNEUUN3ME2yNk44PjRizszN MnjCV2FPT0WU
AM-38 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;FSGlEPTB;MkKuPFY5QSEQvF2= MnzWV2FPT0WU
NCI-H2405 NVjYdJkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIi0cVlKSzVyPUKzMlI2OzNizszN NX;rUmw3W0GQR1XS
M14 MnO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX62XHRJUUN3ME2yN{41ODh6IN88US=> MYrTRW5ITVJ?
ES4 M2D1NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJ|LkSyN|Ih|ryP MYfTRW5ITVJ?
DJM-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPXSWhkUUN3ME2yN{42OjN2IN88US=> MVHTRW5ITVJ?
S-117 NX7JfpRnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{S4SmlEPTB;MkOuO|Y2OSEQvF2= MWDTRW5ITVJ?
MZ2-MEL NFW5V5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXiyc3E4UUN3ME2yN{44PzV7IN88US=> NGL2PGRUSU6JRWK=
SK-MEL-2 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETzOVVKSzVyPUKzMlgyOzNizszN NILLbYFUSU6JRWK=
HCC1806 M4\Dfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJ|Lki3NFkh|ryP MnLEV2FPT0WU
NMC-G1 MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDSO5VKSzVyPUK0MlIzOjZizszN NETyU4ZUSU6JRWK=
DK-MG NHqxXppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nxfmlEPTB;MkSuNlk1KM7:TR?= NFn0eppUSU6JRWK=
SK-N-FI NEXGV|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnT5TWM2OD1{ND6zN|AzKM7:TR?= NWL2cZJPW0GQR1XS
KINGS-1 NE\mN3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;Od5ZKSzVyPUK0MlQ5PzRizszN M1P4fXNCVkeHUh?=
HCC2998 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XnN2lEPTB;MkSuOFg5PSEQvF2= NXrlTnJUW0GQR1XS
ALL-PO MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\mOmxKSzVyPUK0MlYyQSEQvF2= MX;TRW5ITVJ?
MPP-89 NEjteW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\WZ2tKSzVyPUK1MlA1PThizszN NGn0XHlUSU6JRWK=
NCI-H2342 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlvVTWM2OD1{NT6xPVU{KM7:TR?= Ml7WV2FPT0WU
TE-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13pPWlEPTB;MkWuN|U3OyEQvF2= MnrEV2FPT0WU
RH-18 NVvZXY9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjiSYlKSzVyPUK1MlU6OThizszN M2SzOXNCVkeHUh?=
HT-1376 NV:z[Yw6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LBdWlEPTB;MkWuOlQ3PSEQvF2= MVXTRW5ITVJ?
U-2-OS MlHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJ3Lk[4PFgh|ryP NIKxWZNUSU6JRWK=
BT-549 NUH1TVFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jKb2lEPTB;MkWuPVAyOSEQvF2= MYjTRW5ITVJ?
NCI-H1755 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7TVZVKSzVyPUK1Mlk6PDVizszN NVrWZodsW0GQR1XS
EW-13 M4\5V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTJ4LkCyO|Qh|ryP NH3WbolUSU6JRWK=
NB13 M3Plfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XPdWlEPTB;Mk[uNFk1QSEQvF2= NV:5TW9nW0GQR1XS
NUGC-3 NFezbGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJ4LkKxNFMh|ryP MX;TRW5ITVJ?
GMS-10 MlvKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorITWM2OD1{Nj6yN|U{KM7:TR?= M3fnbHNCVkeHUh?=
CHP-134 MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLOeHdKSzVyPUK2MlM5PjdizszN NIezbFhUSU6JRWK=
SW962 M3u0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TRT2lEPTB;Mk[uOVAzOSEQvF2= MkW5V2FPT0WU
SNU-449 M2HUS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPtfpJIUUN3ME2yO{4xQDB|IN88US=> M33SPHNCVkeHUh?=
HuP-T4 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT2TWM2OD1{Nz6wPFc6KM7:TR?= NGHWeHJUSU6JRWK=
SW948 M3PKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn25TWM2OD1{Nz6xN|Q1KM7:TR?= MkfFV2FPT0WU
NCI-H226 Mn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NED6UGtKSzVyPUK3MlQ2PzhizszN MnPqV2FPT0WU
SK-PN-DW NYDle4ZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTJ5Lk[wNVIh|ryP NEThZ|lUSU6JRWK=
GI-1 M1jUc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTJ5LkeyNUDPxE1? MXzTRW5ITVJ?
CAL-12T M2\SUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWO3OZVTUUN3ME2yPE4yOTF{IN88US=> M{HPNHNCVkeHUh?=
YAPC MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJ6LkK1OlQh|ryP M1HPd3NCVkeHUh?=
SNU-C2B M1HDbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f4cmlEPTB;MkiuNlk3PCEQvF2= NH\HdHdUSU6JRWK=
RCC10RGB NHnYSIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTJ6LkW0NVch|ryP M3\1NHNCVkeHUh?=
ES7 MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XNdWlEPTB;MkmuNVQ3PSEQvF2= NFLBWlJUSU6JRWK=
PANC-03-27 NVjSbVZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfETWM2OD1{OT60OFQh|ryP M{m1[HNCVkeHUh?=
ES6 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjURnZKSzVyPUK5MlgyPTdizszN NV36eXJoW0GQR1XS
HT-1197 NUjQT3Z[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTNyLkC1PVgh|ryP M1TpdnNCVkeHUh?=
ZR-75-30 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUftWmdxUUN3ME2zNE4zOzh|IN88US=> MXLTRW5ITVJ?
DB NH22coxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnoeGxKSzVyPUOwMlQ6PDJizszN M4i2VnNCVkeHUh?=
OCI-AML2 NHXGfllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNzLkC2PUDPxE1? MVPTRW5ITVJ?
NCI-H2170 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPENIRKSzVyPUOxMlg2OTZizszN M3PhenNCVkeHUh?=
IST-MES1 NVrINVdPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;NTWM2OD1|Mj6yPFk4KM7:TR?= NXXuZYxGW0GQR1XS
769-P NWXvc45PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Hu[WlEPTB;M{KuN|Y1OSEQvF2= M1zyeXNCVkeHUh?=
COR-L23 NVTZ[IdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTVTWM2OD1|Mj65NFc{KM7:TR?= MXLTRW5ITVJ?
SW626 MmTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkG0TWM2OD1|Mz6xO|c3KM7:TR?= MV\TRW5ITVJ?
LU-139 M{PsdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXyzUIV7UUN3ME2zN{43PjB3IN88US=> M3jnRXNCVkeHUh?=
HT-144 MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTN|Lki2N{DPxE1? NXnCSlZZW0GQR1XS
CaR-1 NIjL[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTN|Lkm4NlIh|ryP NWj4dodiW0GQR1XS
OE33 MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PnbmlEPTB;M{SuNlg2PSEQvF2= NHLWe3JUSU6JRWK=
COLO-800 NYPEfIpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHpbGJKSzVyPUO0MlM3PDdizszN MmPOV2FPT0WU
NB14 MkHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTTTWM2OD1|ND60Olg1KM7:TR?= NYnTO3hLW0GQR1XS
KURAMOCHI MnP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTN4LkGxPVgh|ryP M{TFRXNCVkeHUh?=
SW48 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTN4LkK0O|Qh|ryP NHfiZWNUSU6JRWK=
Daoy NFO5XpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDKTWM2OD1|Nj62OVM5KM7:TR?= MnfSV2FPT0WU
TGBC24TKB MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jHfmlEPTB;M{[uOlch|ryP M1nsWHNCVkeHUh?=
DU-4475 NXPW[3RNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3n5OWlEPTB;M{[uPVA{OyEQvF2= MWjTRW5ITVJ?
SW1417 MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTN6LkC1OVIh|ryP Mn32V2FPT0WU
EFO-21 M1\pcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4S5PWlEPTB;M{iuPVM1QSEQvF2= NVLldIhEW0GQR1XS
MG-63 NH71Z2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTN7LkO0NlQh|ryP MnPTV2FPT0WU
LC-2-ad M4rwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDrTWM2OD1|OT61OVEzKM7:TR?= NF\adFdUSU6JRWK=
NOMO-1 NFnpdYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\QTY9KSzVyPUO5MlgzPzRizszN MXLTRW5ITVJ?
COLO-741 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\ITWM2OD12MD6xN|A1KM7:TR?= M1K5PXNCVkeHUh?=
BxPC-3 NHjvOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHZV2R[UUN3ME20NE42Pjh4IN88US=> NGT2PFdUSU6JRWK=
HSC-2 NEPxdXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLoTWM2OD12MD65NVE{KM7:TR?= M1nK[nNCVkeHUh?=
UMC-11 MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfZTWM2OD12MT6yOlMh|ryP M{PBVnNCVkeHUh?=
HCC1937 M2PmSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjjXWlEUUN3ME20Nk44QDR|IN88US=> M1LPXnNCVkeHUh?=
Calu-6 NFL4d2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLRZ3JRUUN3ME20N{4zOzh{IN88US=> MYjTRW5ITVJ?
NCI-H1573 M2HmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrGbWdKSzVyPUSzMlM1PzdizszN MWXTRW5ITVJ?
SK-N-AS MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXEeWYxUUN3ME20N{43ODF7IN88US=> NFvPOVBUSU6JRWK=
PSN1 NGX4PXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7MR3VKSzVyPUS1MlI2PDhizszN M{DTb3NCVkeHUh?=
TE-11 NGfrR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PTWGlEPTB;NEWuOFg1OiEQvF2= MWrTRW5ITVJ?
NCI-H1155 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnX4TWM2OD12NT64PVY4KM7:TR?= MlTOV2FPT0WU
KM12 M17CcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILYbI5KSzVyPUS1MlkxPzZizszN MnXiV2FPT0WU
RO82-W-1 MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HjPGlEPTB;NE[uPVgzOiEQvF2= MknBV2FPT0WU
SW1573 M{\1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjHbo5{UUN3ME20O{4{PzN4IN88US=> NFnWS5dUSU6JRWK=
CAKI-1 NHTrTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDERWhqUUN3ME20PE4zQDR3IN88US=> MWXTRW5ITVJ?
U-118-MG NViw[WtVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTR6LkO3NFIh|ryP Mn65V2FPT0WU
KYSE-520 NX7HOIVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWWwe4lGUUN3ME20PE41ODF4IN88US=> NUTEO|FtW0GQR1XS
HT55 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWC5U5dZUUN3ME20PU4yPDd2IN88US=> NX;BUmtlW0GQR1XS
ChaGo-K-1 NYDnUHoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkW5TWM2OD12OT60O|k{KM7:TR?= NGnENmdUSU6JRWK=
IA-LM MmjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXJTWM2OD13ND62N|IzKM7:TR?= NV;xSY55W0GQR1XS
UACC-62 M13yNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrte5NKSzVyPUW1MlExPDZizszN NFq4WZFUSU6JRWK=
MKN7 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni3TWM2OD13Nj6wNlg2KM7:TR?= MnrpV2FPT0WU
HPAF-II M2Xsemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUiyeFBMUUN3ME21Ok41ODd|IN88US=> MnXPV2FPT0WU
NTERA-S-cl-D1 NV3lPG5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrUfIJKSzVyPUW3Mlc4QCEQvF2= MW\TRW5ITVJ?
FTC-133 MoHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFv5bpVKSzVyPUW4MlA6PjlizszN NUP6SVhWW0GQR1XS
MHH-ES-1 M2r5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[2[llOUUN3ME21PE41QDF2IN88US=> Mn;3V2FPT0WU
JVM-2 M4XwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTV6Lkm1NFYh|ryP NUHsUJFXW0GQR1XS
TCCSUP M{S3Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrocmJXUUN3ME21PU42Ojd7IN88US=> NGHpOI1USU6JRWK=
COLO-824 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TNeWlEPTB;NkCuNFcyQSEQvF2= M1XyXnNCVkeHUh?=
647-V MkTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHmTWM2OD14MD6xN|Q4KM7:TR?= M1;IUHNCVkeHUh?=
HD-MY-Z NVKzVmM5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTZyLkWyPVQh|ryP NG\IfnNUSU6JRWK=
LS-411N M1nnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zOVGlEPTB;NkGuN|kxOyEQvF2= NUXxNGJtW0GQR1XS
NCI-H596 Mlv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3jPZlqUUN3ME22Nk44PDl4IN88US=> MVjTRW5ITVJ?
C-33-A MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjwTWM2OD14ND6wPVU4KM7:TR?= NILOcmdUSU6JRWK=
BHY MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPGTWM2OD14ND6xNlQ2KM7:TR?= M2nOWnNCVkeHUh?=
KGN MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;YTWM2OD14ND61OVE1KM7:TR?= NFHsNmZUSU6JRWK=
NCI-H1092 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTZ3LkCwPVUh|ryP MUDTRW5ITVJ?
MZ1-PC M4Dwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHWXos4UUN3ME22OU42PjR7IN88US=> MXPTRW5ITVJ?
LB831-BLC Mk\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTZ3Lki0PFEh|ryP NIDIcXNUSU6JRWK=
SW620 NHfrWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTZ4LkKwN|kh|ryP MmP5V2FPT0WU
HuO-3N1 MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDOZVRpUUN3ME22PE4{OjN6IN88US=> NUDrVolTW0GQR1XS
SK-HEP-1 MnS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;rSGlEPTB;NkmuPVQ5PiEQvF2= MX7TRW5ITVJ?
LCLC-103H NIP4SYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\m[ZRuUUN3ME23NE43PzB3IN88US=> NWn4N3VnW0GQR1XS
KYSE-70 NXXKPZVDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HWPWlEPTB;N{CuO|g{PSEQvF2= MU\TRW5ITVJ?
Mewo MkPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fvT2lEPTB;N{GuOVA2KM7:TR?= NWf4RYVnW0GQR1XS
COLO-668 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzZc4FKSzVyPUexMlg1PTFizszN NXjrVZRoW0GQR1XS
NCI-H522 Ml7oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzyWXFJUUN3ME23Nk4{PDF|IN88US=> Mn3CV2FPT0WU
NCI-H1437 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLOTWM2OD15ND60NFQ5KM7:TR?= MojyV2FPT0WU
U-266 NX2yUWtZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTd3LkS1NVYh|ryP NFHDSIJUSU6JRWK=
MC116 M2H5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2OwdWlEPTB;N{WuOVcxQCEQvF2= MUfTRW5ITVJ?
PANC-10-05 NXTyVVkyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;WcoNKSzVyPUe3MlQzPDNizszN MUjTRW5ITVJ?
KYSE-180 MmT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDjd2pKSzVyPUe3MlU1PTRizszN M3XmWHNCVkeHUh?=
JAR NVrkR|hnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPSNXZ[UUN3ME23PU4xPTR4IN88US=> M1zLNHNCVkeHUh?=
CAL-62 NUPEPZNsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DEfGlEPTB;OECuNFk2KM7:TR?= NFnSc5BUSU6JRWK=
A3-KAW NUf4U4NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\QWGlEPTB;OECuNlE2PCEQvF2= M1nVcHNCVkeHUh?=
PANC-08-13 NYDFcmtmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPtTWM2OD16MT6xO|Y5KM7:TR?= M2rnZnNCVkeHUh?=
HSC-3 NUHzSZA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\Pe2xKSzVyPUizMlMxPzFizszN MmPWV2FPT0WU
HTC-C3 MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3e2cGlEPTB;OEOuOFcxOiEQvF2= NEHySZdUSU6JRWK=
KY821 MkTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfHcGxKSzVyPUi0MlA5QTJizszN MWHTRW5ITVJ?
DoTc2-4510 NInpfWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTh2LkKxPFUh|ryP M4i5WXNCVkeHUh?=
NCI-H1581 MkTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTIb5dKSzVyPUi1MlQ3PDFizszN Ml\YV2FPT0WU
KARPAS-299 NY\n[5dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{exV2lEPTB;OE[uNVk4PyEQvF2= MWrTRW5ITVJ?
IST-MEL1 NYroVXp2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvUTWM2OD16Nj64PFczKM7:TR?= NIPTd2VUSU6JRWK=
KP-N-YS NWO4cIpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTh7LkmwNlgh|ryP NFvxO2ZUSU6JRWK=
KYSE-410 NH7yOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTlzLkSwOFIh|ryP M2f5[3NCVkeHUh?=
TE-10 MlfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfwS2JKSzVyPUmxMlU3OTFizszN M3zhXnNCVkeHUh?=
SK-MEL-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTl{LkmxNFYh|ryP M374T3NCVkeHUh?=
COLO-792 NWKyOHJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u1cGlEPTB;OUWuNlU3PCEQvF2= NF\1ZmpUSU6JRWK=
SCH NX[xO45iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7hWVlFUUN3ME25Ok4{QDd5IN88US=> MWjTRW5ITVJ?
NCI-H1792 Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\FOGlEPTB;OU[uPFk6OiEQvF2= MlLsV2FPT0WU
NCI-H2029 MlHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGW4[5VKSzVyPUm2Mlk2PjZizszN MWjTRW5ITVJ?
SW684 NVvLSIluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\Qbm1KSzVyPUm4MlY3PTRizszN NIHoZ4FUSU6JRWK=
NCI-H209 NX\qPHJlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkL3TWM2OD1zMECuNVIyKM7:TR?= NFL4TmRUSU6JRWK=
HLE NEjaXVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7zTWM2OD1zMEWuNlgzKM7:TR?= MXvTRW5ITVJ?
GOTO M{L5eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXuT3d4UUN3ME2xNFcvPzd5IN88US=> NEP3VJNUSU6JRWK=
NCI-H1793 NFHiOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHSVpBOUUN3ME2xNFkvOjhizszN MkPIV2FPT0WU
D-392MG M3;u[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3m2[2lEPTB;MUG3MlM6QCEQvF2= MXjTRW5ITVJ?
SW1990 NXXW[o9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoWxTWM2OD1zMkCuPVUyKM7:TR?= MVPTRW5ITVJ?
ML-2 M2f2PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPEbZlxUUN3ME2xNlEvPjd4IN88US=> MUTTRW5ITVJ?
NCI-H2452 MkLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELCXm9KSzVyPUGyNk4zOSEQvF2= MoqzV2FPT0WU
SK-MEL-30 M3uybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;IXItEUUN3ME2xNlMvOjR2IN88US=> NVHQSFRjW0GQR1XS
SN12C MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTmc3B1UUN3ME2xNlQvOTd4IN88US=> M4Pzc3NCVkeHUh?=
NCI-H1770 M2\XN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf1VmlKSzVyPUGyOU42OTRizszN M3TtcHNCVkeHUh?=
SF268 MoCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorOTWM2OD1zMk[uNVU5KM7:TR?= MWfTRW5ITVJ?
BALL-1 MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTF{Nj6yN{DPxE1? NVXCUYpQW0GQR1XS
COLO-679 M{DTVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTF{Nj63OVMh|ryP M{PncHNCVkeHUh?=
A2780 NF;LNlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzjTWM2OD1zMkiuPVg5KM7:TR?= MYLTRW5ITVJ?
NCI-H1651 NX24bpdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HvOWlEPTB;MUOxMlI1OyEQvF2= NV72OmpZW0GQR1XS
NCI-H2087 M{njcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHNU3dKSzVyPUGzNU41QDNizszN M4nHTHNCVkeHUh?=
U-87-MG NHqxT2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rNXGlEPTB;MUOzMlYxPCEQvF2= MUPTRW5ITVJ?
LB2518-MEL MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTF|NT65PVMh|ryP NHHFRolUSU6JRWK=
HCT-116 NVr5dmljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\oXItYUUN3ME2xN|cvOjF5IN88US=> NUj3cJU2W0GQR1XS
Ca9-22 NWW1ZYRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTF|OT64N|Mh|ryP M{H3UnNCVkeHUh?=
COR-L88 MlvMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrlboJKSzVyPUG0Nk4yPCEQvF2= M4\4[XNCVkeHUh?=
CP50-MEL-B MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTF2ND61NFEh|ryP NGm0XIJUSU6JRWK=
OVCAR-8 NE\Ue2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTF2NT62N|Yh|ryP Mn7iV2FPT0WU
SK-MEL-3 NYHvSo5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTF2Nz64O|gh|ryP M3nTdXNCVkeHUh?=
GT3TKB MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTF2OT65Nlgh|ryP MUDTRW5ITVJ?
KYSE-450 M2TXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\4PZJZUUN3ME2xOVEvPTN7IN88US=> MkPZV2FPT0WU
CAPAN-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LEPWlEPTB;MUWzMlA3PCEQvF2= NVfHTlNCW0GQR1XS
BEN MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjVTWM2OD1zNUOuPVI5KM7:TR?= M3jJWHNCVkeHUh?=
NCI-H1304 NXyxeZp4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFeydGpKSzVyPUG1OE43QTRizszN MYDTRW5ITVJ?
KU812 NIX0TldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTF3OD62O|Qh|ryP MnvqV2FPT0WU
Capan-2 MmHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfVfmJKSzVyPUG2NE42PTNizszN NVHZcXp1W0GQR1XS
A673 MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS4ZoM3UUN3ME2xOlEvPzB3IN88US=> MknmV2FPT0WU
SAS NUjGVFdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTF4Mj62O|gh|ryP MUXTRW5ITVJ?
NY MkjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljJTWM2OD1zNkWuN|E1KM7:TR?= NX3le|Z4W0GQR1XS
HCE-4 NYDPe|BVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDIT49NUUN3ME2xOlYvQDR3IN88US=> NWD3c3hrW0GQR1XS
MDA-MB-231 NG\wSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTJN451UUN3ME2xO|cvPTB|IN88US=> MoL1V2FPT0WU
no-10 M{f3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTF5OD6xN|Qh|ryP M3nGVHNCVkeHUh?=
MZ7-mel MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTF5OD60Olch|ryP NFXBeJBUSU6JRWK=
NCI-H82 MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrrTWM2OD1zOECuNVY2KM7:TR?= MmmwV2FPT0WU
CAL-72 NEX6O41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrxO3ZKSzVyPUG4OU4xPTRizszN M{LqRnNCVkeHUh?=
NCI-SNU-5 NX7IWmdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrWW|RVUUN3ME2xPFYvQDRizszN NIrlTndUSU6JRWK=
OVCAR-4 NXH2W2N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEf1V4lKSzVyPUG4PE4{OzNizszN Mk\GV2FPT0WU
SCC-9 MnnwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTF7MTFOwG0> NV7m[2h[W0GQR1XS
KYSE-150 M4Thdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHaeolKSzVyPUG5NU45QDhizszN Mo\PV2FPT0WU
HT-29 MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnKTWM2OD1{MEGuNlEzKM7:TR?= NXXsfnIyW0GQR1XS
COLO-678 M{j4VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moi2TWM2OD1{MEGuOFUh|ryP M4jFUHNCVkeHUh?=
NCI-H650 NViyc4M6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;KNoxKSzVyPUKwNk4yODNizszN NWDEdYZ4W0GQR1XS
HuCCT1 M3zKdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTYdpVKSzVyPUKwOE4zODhizszN NUPoRVhqW0GQR1XS
SW1116 NVvUdXBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rzdmlEPTB;MkC3MlA4PyEQvF2= MXPTRW5ITVJ?
DBTRG-05MG NXX3bJk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfoTWM2OD1{MEeuPVA6KM7:TR?= MYnTRW5ITVJ?
SW982 MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHtTWM2OD1{MEeuPVQ5KM7:TR?= MnrIV2FPT0WU
RCM-1 NH;z[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTJzND63OlIh|ryP NHLi[oxUSU6JRWK=
COLO-320-HSR MlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmqxTWM2OD1{MU[uNVI2KM7:TR?= MmC4V2FPT0WU
KNS-42 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfMOnFKSzVyPUKxOk42PzRizszN NGDyO4lUSU6JRWK=
C2BBe1 NIL5eIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFW0UZpKSzVyPUKzNU46ODVizszN MmPSV2FPT0WU
CCRF-CEM M1P6PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{izRWlEPTB;MkSzMlc6PSEQvF2= MYPTRW5ITVJ?
SH-4 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnCVIZKSzVyPUK0Ok4xQSEQvF2= NIKzc41USU6JRWK=
LS-1034 NIXMPIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1PFbWlEPTB;MkS2MlI3PiEQvF2= MkHkV2FPT0WU
NCI-H2347 NIWxe2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLDOnd1UUN3ME2yOFcvPzF|IN88US=> MkT0V2FPT0WU
RPMI-8866 Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTRfnJwUUN3ME2yOFkvOjdizszN NUm5TYlYW0GQR1XS
GAK M{DPVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPITWM2OD1{NUOuNFAzKM7:TR?= MVzTRW5ITVJ?
NB6 NU\qUYFbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NID6UZRKSzVyPUK3NE4yKM7:TR?= Mo[5V2FPT0WU
COLO-680N NYD4NGVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEOzboZKSzVyPUK3Nk42OjdizszN NYHEfXM5W0GQR1XS
RERF-LC-MS NGTvW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;uVIdEUUN3ME2yO|YvODB5IN88US=> M2T3SnNCVkeHUh?=
TGBC11TKB M2XqNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnaTWM2OD1{N{iuNVc5KM7:TR?= M4TZdnNCVkeHUh?=
C8166 MkXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULETXJ1UUN3ME2yO|gvPTB4IN88US=> MULTRW5ITVJ?
HDLM-2 NH76T|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zqdWlEPTB;Mkm0MlQxQSEQvF2= MmOwV2FPT0WU
IGR-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDjZZhRUUN3ME2yPVUvPjV7IN88US=> MnPkV2FPT0WU
FADU NVXjSZpMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTJ7Nz61NUDPxE1? NFnOToVUSU6JRWK=
L-428 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITsUolKSzVyPUK5O{43OTZizszN MkO1V2FPT0WU
LU-65 NX34OFJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrwUpdKSzVyPUOwOE4{OiEQvF2= MXfTRW5ITVJ?
HEL MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTNyOT65PFMh|ryP MXHTRW5ITVJ?
NCI-H810 MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIX2UVZKSzVyPUOxNE42PyEQvF2= MmTUV2FPT0WU
C3A Ml;OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\1TWM2OD1|MUGuPFAzKM7:TR?= MYDTRW5ITVJ?
NCI-H630 MkjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\ieZdsUUN3ME2zN|IvOjl2IN88US=> MkfqV2FPT0WU
KP-N-YN M4rDW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnsTYRKSzVyPUO0NU4yOjNizszN MWDTRW5ITVJ?
MOLT-13 NVfZVJo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LxbWlEPTB;M{SyMlMzPiEQvF2= NHTPN3JUSU6JRWK=
NCI-H1993 M4XWNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;YTWM2OD1|NEKuN|Y2KM7:TR?= M1y3fXNCVkeHUh?=
BE-13 NX3qRopiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTN2ND6xOlch|ryP NG\zTWZUSU6JRWK=
IST-SL1 M1S1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWW4c3VMUUN3ME2zOFcvPDBzIN88US=> MXnTRW5ITVJ?
TE-9 Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf1TWM2OD1|NkOuOVg6KM7:TR?= M4jDTXNCVkeHUh?=
LU-135 MkPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfYWJluUUN3ME2zOlcvODN3IN88US=> MXLTRW5ITVJ?
T84 NEG5NFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTN5ND63NVIh|ryP NHzCPI5USU6JRWK=
K-562 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlS5TWM2OD1|OEOuN|Yh|ryP NGfoWpFUSU6JRWK=
SBC-5 NFHjcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3nfWh7UUN3ME2zPFYvQTh3IN88US=> MV;TRW5ITVJ?
NB17 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfxd|Y2UUN3ME2zPVIvPTl4IN88US=> MWLTRW5ITVJ?
NCI-H2052 NI\5cotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7FWVZVUUN3ME2zPVgvPDd{IN88US=> NH71UGNUSU6JRWK=
HCC38 NUTROlhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTRyMT61PVMh|ryP Mn;sV2FPT0WU
NCI-H69 NU\0cXppT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTR2MT6wPFMh|ryP NWflbWhLW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]

Protocol

Kinase Assay:[4]
+ Expand

Akt kinases assay:

Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.
Cell Research:[2]
+ Expand
  • Cell lines: A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
  • Concentrations: 0, 0.3, 1 and 3 μM
  • Incubation Time: 72 or 96 hours
  • Method: MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
  • Formulation: Formulated in 30% Captisol
  • Dosages: 120 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL (29.14 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 15% Captisol 17 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 480.39
Formula

C25H21N5O.2HCl

CAS No. 1032350-13-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01306045 Recruiting Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung|Carcinoma, Thymic National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 21, 2011 Phase 2
NCT01802320 Active, not recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Active, not recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Carcinoma National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Active, not recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID